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ABSTRACT 16 
The main aim of the research focused on the production of hot-melt extrusion (HME) 17 
formulations with increased dissolution properties of albendazole (ABZ). Therefore, HME 18 
was applied as a continuous manufacturing technique to produce amorphous solid dispersions 19 
of the poorly water soluble drug ABZ combined with the polymer matrix 20 
polyvinylpyrrolidone PVP K12. HME formulations of ABZ ± PVP K12 comprised a drug 21 
content of 1%, 5% and 10% w/w. The main analytical characterisation techniques used were 22 
Scanning Electron Microscopy (SEM), Micro-computed Tomography (µ-CT), X-Ray Powder 23 
Diffraction (XRPD), Differential Scanning Calorimetry (DSC) and dissolution profile 24 
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studies. The application of SEM, XRPD and DSC evidenced drug physical transformation 25 
from crystalline to amorphous state and therefore, the achievement of an amorphous solid 26 
dispersion. The introduction of a novel technique, µ-CT, to characterise the internal structure 27 
of these materials revealed key information regarding materials distribution and void content. 28 
Dissolution profile studies evidenced a high increase in drug release profile compared to pure 29 
ABZ. These promising results can lead to a great enhancement of the oral bioavailability of 30 
ABZ dosage forms. Therefore, HME is a potential continuous manufacturing technique to 31 
overcome ABZ poor solubility properties and lead to a significant increase in the therapeutic 32 
effect. 33 
Keywords: Hot-melt extrusion; Amorphous solid dispersions; Albendazole; Continuous 34 
manufacturing; µ-CT. 35 
1. Introduction 36 
A major focus of current pharmaceutical industry research is directed at the need to 37 
manufacture and deliver better quality medicines in a cost efficient manner (Madan and 38 
Madan, 2012). However, the physicochemical properties of Active Pharmaceutical 39 
Ingredients (APIs) are not always ideal and properties such as poor aqueous solubility, which 40 
influences dissolution and oral bioavailability, can be detrimental during pharmaceutical 41 
development (Munos, 2009; Kawakami, 2012). APIs that exhibit low solubility properties but 42 
high permeability through biological membranes are considered Class II compounds within 43 
the Biopharmaceutics Classification System (BCS) (Lindenberg et al., 2004) and in order to 44 
overcome poor solubility properties several formulation techniques can be considered. Some 45 
of the most common approaches are the introduction of chemical transformations such as the 46 
production of salt or co-crystal forms and other process modifications for example drug 47 
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micronisation or the production of amorphous solid dispersions (Stegemann et al., 2007; 48 
Kawabata et al., 2011; Jones et al., 2014). 49 
It has been recognised that a change in the $3,¶Vmolecular physical state from a crystalline 50 
ordered structure to an amorphous state dramatically enhances its solubility and dissolution 51 
properties (Zhang et al., 2004). This physical transformation of the drug can be achieved by 52 
Hot-Melt Extrusion (HME) in order to deliver an amorphous solid dispersion with increased 53 
dissolution properties, which is controlled by the polymeric carrier excipient combination 54 
employed.  55 
HME is a widely known manufacturing process that has been used in the plastic (Michaeli et 56 
al., 1993) and food industries (Cheng and Friis, 2010) and more recently, in the 57 
pharmaceutical industry (Crowley et al., 2007). In HME, a hydrophilic polymeric carrier and 58 
a poor water soluble drug are homogeneously mixed to form a molecular solid dispersion 59 
(Repka et al., 2007). HME can be achieved using a single or twin-screw extruder, both types 60 
have been widely studied and the advantages and disadvantages regarding the material 61 
mixing achieved reviewed (Van zuilichem et al., 1999). Selection of the components must be 62 
carefully performed taking into account the melt temperature (Tm) of both the polymer and 63 
the API as well as the glass transition temperature (Tg) of the polymer. These parameters 64 
play a key role in obtaining an amorphous solid dispersion as well as being key determinants 65 
of product stability (Newman et al., 2012). Initial assessment of the solubility properties can 66 
be performed by evaluating drug-polymer miscibility properties or also by using a 67 
mathematical approach such as the Hoy and Hoftzyer/Van Krevelen method (Forster et al., 68 
2001). After production, characterisation techniques such as X-Ray Powder Diffraction 69 
(XRPD) and thermal analysis by Differential Scanning Calorimetry (DSC) constitute 70 
important techniques for the assessment of drug solid state (Maniruzzaman et al., 2013). 71 
Previous HME applications have focused on the development of new drug delivery systems 72
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such as sustained released or taste-masking formulations (Maniruzzaman et al., 2012; Gue et 73 
al., 2013; Schilling and McGinity, 2010; Verhoeven et al., 2009b). By applying modelling 74 
techniques such as Computational Fluid Dynamics (CFD), Eitzlmayr et al., (2014), 75 
demonstrated that HME processes can be fully designed and noted the importance of 76 
selecting adequate screw elements configuration as this has an impact on the screws filling 77 
degree and therefore the heat transfer mechanisms within the extruder. Moreover, processing 78 
parameters such as melt temperature can be calculated taking into account the polymer¶s and 79 
API¶s viscosity values. Finally Quality by Design (QbD) has emerged as a potent tool to 80 
investigate the working space limits of HME processes based on the desired product 81 
specifications (Thiry et al., 2015; Maughan and Rhamzan, 2012). 82 
The main aim of this research comprised the development and characterisation of novel 83 
albendazole (ABZ) formulations manufactured by continuous HME processing to improve 84 
ABZ dissolution properties and determine the influence of different drug contents in relation 85 
to material properties such as drug content uniformity, materials homogeneity and internal 86 
porosity by the application of a novel technique such as micro computed tomography (µ-CT). 87 
ABZ is an anthelmintic drug used in the treatment of hydatid disease, among other parasitic 88 
worm infestations. Reported physicochemical properties of ABZ such as a low aqueous 89 
solubility of 0.0228 mg/mL and a melting temperature (Tm) of 208°C were crucial to 90 
determine the suitability of this drug molecule for HME processing. APIs with a high melting 91 
point are preferred to avoid any degradation product as it has been previously observed using 92 
temperature sensitive drugs. It is also widely known that the low solubility and dissolution 93 
rate of ABZ lead to erratic absorption (below 5%) from the gastrointestinal tract mainly 94 
observed through pharmacokinetic studies (Marriner et al., 1986; Jung et al., 1998). 95 
Moreover, Newman et al., (2012), classified ABZ as one of the BCS II compounds where a 96 
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solid phase transformation using a hydrophilic polymer such as PVP could become a suitable 97 
approach towards the enhancement of its oral bioavailability. 98 
Previous work comprising solid dispersions of ABZ and PVP K12 manufactured by solvent 99 
evaporation method was carried out by Torrado et al., (1996) in order to improve ABZ 100 
dissolution rate. In our study we were able to successfully produce stable amorphous solid 101 
dispersions of ABZ by HME process with increased dissolution properties and provide novel 102 
characterisation studies by the application of µ-CT. 103 
2. Materials and methods 104 
2.1. Materials 105 
Albendazole (ABZ,  %) was purchased from Sigma-Aldrich Company Ltd. (Gillingham, 106 
Dorset, United Kingdom). Pharmaceutical grade polyvinylpyrrolidone K12 (PVP K12 PF), 107 
was kindly donated by BASF (Cheshire, United Kingdom). Other reagents such as methanol 108 
(HPLC grade,  %), potassium chloride AR grade, sodium dihydrogen phosphate (>99.0 109 
%) and glacial acetic acid (ACS reagent,  %) were obtained from Sigma-Aldrich. 110 
2.2. Miscibility studies 111 
Miscibility properties of ABZ and PVP K12 were theoretically assessed using the Hansen 112 
solubility parameter calculations and confirmed by hot-stage microscopy (HSM) using a 113 
Reichert-Jung polyvar optical microscope fitted with a hot-stage. Raw materials, physical 114 
mixtures (PM) at 1/99, 5/95 and 10/90 % w/w and extruded materials were studied using a 115 
heating rate of 10 °C/min. 116 
2.3. Continuous manufacturing by Hot-Melt Extrusion (HME) 117 
Formulations of ABZ and PVP K12 comprising 1/99, 5/95 and 10/90 (% w/w) (F1, F2 and 118 
F3, total sample weight of 50 g) were prepared (Jones et al., 2014; Kelly et al., 2015). 119 
Previous sieving of PVP K12 through a mesh of 250 µm was carried out for particle size 120 
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homogenisation purposes. Physical mixtures of ABZ ± PVP K12 were manually blended for 121 
2-5 minutes prior extrusion. All formulations were processed by HME using a Thermo 122 
Scientific® Process 11 co-rotating twin-screw  extruder (40L/D) (Karlsruhe, Germany) with 123 
the following standard screw configuration: (FS 11/40) x 7 + (KE 10/90°) x 8 + (KE 10/60°) 124 
x 4(F) + (FS 11/40) x 8 + (KE 10/60°) x 6(F) + (FS 11/40) x 7 + (KE 10/90°) x 4 + (KE 125 
10/60°) x 3(F) + (KE 10/30°) x 5(F) + (FS 11/40) x 9; (FS 11/40: feed screw with a pitch of 126 
11 mm and length of 40 mm; KE 10/90°: kneading element with thickness of 10 mm and 90° 127 
offset angle; KE 10/60°: kneading element with thickness of 10 mm and 60° offset angle; KE 128 
10/30°: kneading element with thickness of 10 mm and 30° offset angle; F: forward). The 11 129 
mm screw diameter extruder was fitted with a single orifice die of 2.0 mm diameter and 130 
processing parameters are presented in Table 1. Cooling of the strands was performed at 131 
room temperature and then stored in a sealed glass container under temperature controlled 132 
conditions of 25 °C and 50 °C. Initial studies of all extruded materials were performed at zero 133 
time and stability studies performed after 1, 3 and 6 months storage under conditions 134 
indicated in the text. 135 
2.4. Scanning Electron Microscopy (SEM) 136 
HME formulations containing ABZ ± PVP K12 were analysed by SEM for the presence of 137 
crystalline ABZ. Gold-coated samples of the extruded materials were mounted on the sample 138 
holder using silver paint and uncoated samples of pure ABZ and physical mixtures ABZ ± 139 
PVP K12 were mounted using double-sided conductive tape. Measurements were performed 140 
using a Hitachi SU 6600 high-resolution analytical FE-SEM (New York, United States) at 141 
5.00 and 20.00 kV and a Zeiss IS50 (Oberkochen, Germany) at 20.00 kV. 142 
2.5. Computed Tomography (µ-CT) 143 
Cross-sections of the extruded materials were analysed by CT x-rays scanning to assess the 144 
internal void content (porosity) at a microstructural level, as well as sample uniformity by the 145 
International Journal of Pharmaceutics 
 
7 
 
characterisation of the average molecular densities. A Bruker high resolution X-ray Micro-146 
CT SkyScan 1272 (Kontich, Belgium) with an X-ray source voltage of 50 kV was used. The 147 
system was equipped with an aluminium 0.25 mm filter and 11 Mp CCD detector. Sample 148 
preparation required the introduction of a piece of extruded material inside a drinking straw 149 
to avoid any interference due to sample movement during measurement. Extruded material of 150 
ABZ ± PVP K12 at 1/99 (% w/w) was analysed using a rotation step of 0.6° and extruded 151 
materials at 5/95 and 10/90 (% w/w) a rotation step of 0.10° and exposure time of 300 ms. 152 
The scanned images were reconstructed using the NRecon software (version 1.6.9.18, Bruker 153 
Micro-CT, Kontich, Belgium). To visualise and analyse the data, CTAn software (version 154 
1.14.4.1, Bruker, Micro-CT, Kontich, Belgium) and CTVol software (version 2.2.3.0, Bruker 155 
Micro-CT, Kontich, Belgium) for surface rendering were used. A set of calculations within 156 
CTAn including image thresholding were applied to determine a region of interest (ROI) 157 
within the cross section of the extruded material and avoid any interference caused by the 158 
straw. Porosity calculations were performed considering the volume of internal closed pores 159 
which are completely surrounded by solid material. 160 
2.6. X-Ray Powder Diffraction (XRPD) 161 
All extruded materials were analysed by XRPD in order to determine the molecular 162 
transformation of the drug from crystalline to amorphous state. A Bruker AXS D8 advanced 163 
transmission diffractometer (Karlsruhe, Germany) with theta-theta geometry, primary 164 
PRQRFKURPDWLF UDGLDWLRQ &X .ĮȜ = 1.54056 Å), a Braun 1D position sensitive detector 165 
(PSD) and an automated multi-position x-y sample stage were used. Raw materials and 166 
physical mixtures drug-polymer were also characterised, and their XRPD patterns compared 167 
with the extruded materials. 168 
2.7. Differential Scanning Calorimetry (DSC) 169 
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Thermal analysis of the extruded materials, physical mixtures drug-polymer and raw 170 
materials was performed using a Mettler Toledo DSC 822e (Greifensee, Switzerland) 171 
differential scanning calorimeter. A standard In/Zn calibration was performed and an inert 172 
gas such as N2 was used to purge throughout the equipment at 150 mL/min. Samples were 173 
ground using a mortar and pestle then introduced into 40 µl sealed aluminium crucibles with 174 
a pierced lid. All samples were heated from 25 to 250 °C, melting temperature (Tm) of ABZ 175 
(208-210 °C), at a heating rate of 10 °C/min, data was evaluated using the Star® Evaluation 176 
Software and the Tg events were characterised using the inflection method.   177 
2.8. Karl-Fischer studies for stability evaluation 178 
A Mettler Toledo DL-39 Karl-Fischer instrument (Schwerzenbach, Switzerland) was used to 179 
assess the water content of the extruded materials after 1, 3 and 6 months storage. Previous 180 
sample preparation required grinding of the sample using a mortar and a pestle followed by 181 
dissolution of 10 mg of extruded material in 1 mL of methanol. Experiments were performed 182 
in chambers with controlled temperature and RH. 183 
2.9. Dissolution profile studies 184 
Dissolution studies of the extruded materials and physical mixtures were carried out using a 185 
Sirius T3 measurement system (East Sussex, United Kingdom). Sample preparation required 186 
manual grinding using a mortar and a pestle to a fine powder. Particle size distributions of 187 
these materials were analysed (sample measurement time of 3 s) using a Malvern Mastersizer 188 
3000 (Worcestershire, United Kingdom) fitted with the Aero S dry dispersion unit, a micro 189 
tray and air pressure adjusted to 1 bar. Mean values (d10, d50, d90) obtained for PM of ABZ ± 190 
PVP K12 at 1/99, 5/95 and 10/90 % w/w were 21.11, 61.09, 110.38 µm, 15.41, 50.48, 97.78 191 
µm and 10.55, 46.11, 90.46 µm, respectively. Moreover, mean values (d10, d50, d90) of 192 
extruded materials at 1/99, 5/95 and 10/90 % w/w were 33.93, 197.46, 463.48 µm, 18.01, 193 
123.54, 425.15 µm and 8.65, 88.90, 459.85 µm, respectively. Later sample preparation 194 
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included the formation of a 3 mm diameter single tablet by weighing between 7 to 12 mg of 195 
grinded material that was later considered for dosage adjustment of each formulation. Tablets 196 
were pressed using a custom made die and a Specac manual hydraulic press (Kent, United 197 
Kingdom) with a compaction pressure of 80 kN. A Sirius T3 measurement system was then 198 
used to obtain material dissolution profiles between pH values of 2 to 7. A stationary disk 199 
apparatus was used consisting of a tablet holder where die and tablet were inserted and 200 
analysed using 15 mL of acetate phosphate buffer dissolution media. The buffer media was 201 
used to simulate in-vitro gastrointestinal conditions by pH automatic adjustment from 2.0-3.7 202 
(time 0-30min), 3.7-5.2 (time 30-60min), 5.2-7.1 (time 60-90min), and 7.1 (time 90-130min) 203 
and tablet surface facing the media to facilitate tablet erosion. Physical mixtures as well as 204 
extruded materials produced were analysed under non-sink conditions by a titration method. 205 
Datapoints were collected every 30 seconds by an spectroscopic UV dip-probe at a 206 
wavelength of 250 nm and transformed using pKa values (4.08; 10.34) and Molar Extinction 207 
Coefficient (MEC) into dissolution profile curves representing drug release (%) over time. 208 
3. Results and discussion 209 
3.1. Miscibility studies 210 
The application of the Hoy and Hoftzyer/Van Krevelen method through the Hansen solubility 211 
parameter calculation evidenced that ABZ and PVP K12 are highly miscible, with a solubility 212 
SDUDPHWHUGLIIHUHQFHǻįRI03D1/2,QGLYLGXDOVROXELOLW\SDUDPHWHUYDOXHVįIRU$%=213 
and PVP K12 were previously calculated based on the contribution of dispersive forces (Ed), 214 
polar interactions (Ep) and hydrogen bonds (Eh). Physical mixtures of ABZ and PVP K12 215 
were also characterised by Hot-Stage Microscopy (HSM) to assess the miscibility properties 216 
of the two components and also their suitability for HME processing. Figure 1, a-d illustrates 217 
pure ABZ sample and images e-g the results of the physical mixture of ABZ ± PVP K12 at 218 
10/90 (% w/w) under different temperature conditions. Solid ABZ appears as dark crystals 219 
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using a 10x magnification lens, similar to the results observed by Moyano et al., (2014) using 220 
100x magnification. In their study, commercial ABZ melting event is characterised at an 221 
onset temperature of 186 °C and complete melting is observed at 216 °C. Similar results are 222 
shown in Figure 1, images a to d where commercial ABZ particles are stable at temperatures 223 
between 45 to 180 °C but complete melting event is shown at 210 °C. A physical mixture, 224 
ABZ ± PVP K12 at 10/90 (% w/w), shows a characteristic birefringence property that allows 225 
the differentiation between amorphous polymer and ABZ crystals (Fig. 1, e to g). Initial 226 
stages of polymer melting can be observed at a temperature of 145 °C (Fig. 1f) similar to 227 
DSC thermal analysis behaviour observed by Baird and Taylor (2012) and at 180 °C, drug 228 
crystals dissolve within the polymer indicating the miscibility properties of the two materials 229 
(Fig. 1g). These results confirm the ability of ABZ and PVP K12 to form a miscible system 230 
when temperatures above the Tg of the polymer are applied (Tg of PVP K12 = 90 °C) 231 
(Reintjes, 2011). 232 
3.2. Scanning Electron Microscopy (SEM) 233 
All formulations processed by HME were characterised by SEM microscopy in order to 234 
assess the physical state of the drug within the polymeric matrix, and extruded materials 235 
appear to be homogeneous when compared to the physical mixtures (Figure 2, b to d). It was 236 
also observed that as the amount of drug increased the porosity within the samples also 237 
increased which suggests that there is a correlation between the PVP K12 polymer and the 238 
proportion of drug in the system with the relaxation properties exhibited by the extruded 239 
materials (Sarode and Kumbharkhane, 2012). Moreover, polymer surface analysis of 240 
extruded materials (Figure 2, e to g) suggests the presence of a laminated surface 241 
characteristic of all samples. 242 
3.3. Computed Tomography (µ-CT) 243 
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Extruded materials were scanned using a µ-CT instrument in order to show at a micro-244 
molecular level the homogeneity properties and suitability of HME technique to obtain a high 245 
mixing degree product. Previous studies to assess drug content uniformity within HME 246 
systems incorporated a fluorescent dye (Park et al., 2013) however characterisation of 247 
materials internal structure by computed tomography (CT) has gained popularity as a useful 248 
tool to examine solid dosage forms such as tablets (Sinka et al., 2004) or granule 249 
intermediates (Crean et al., 2010) and more recently co-extruded materials (Vynckier et al., 250 
2015). This technique offers the possibility to analyse the PDWHULDO¶V internal structure 251 
through X-rays scans and visualise density and porosity characteristics. Extruded materials 252 
comprising ABZ ± PVP K12 at 1/99, 5/95 and 10/90 (% w/w) were analysed by µ-CT (Fig. 3, 253 
a-c) and the cross-section visualised by density characterisation shows an increase in porosity 254 
as well as different density levels from low (red) to medium (green) and high (blue) density 255 
values that correspond to the densities of air, polymeric material such as PVP K12 and ABZ. 256 
The porosity as shown in Figure 3 could be explained by entrapped air or by electrostatic 257 
interactions that occurred between ABZ and PVP K12. Moreover, 3D analysis and 258 
differences in the morphometric parameters obtained for all extruded materials can be 259 
observed in Table 2. It is then evidenced that the degree of porosity is influenced by the drug 260 
content within the extruded material and this is the first report of non-homogeneity in 261 
extruded materials at a micro-structural level. This is similar to reported micro-structure 262 
variations for tablets (Sinka et al., 2004), granules (Crean et al., 2010) and calendered tablets 263 
(Vynckier et al., 2015) where it was observed the influence of pores formed during co-264 
extrusion into tablet adhesion degree between core and coat. Such studies indicate that 265 
despite the known mixing ability of twin-screw processing (Crowley et al., 2007) standard 266 
techniques for assessing homogeneity may not be adequate. 267 
3.4. X-Ray Powder Diffraction (XRPD) 268 
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The XRPD patterns of ABZ ± PVP K12 extruded formulations, drug-polymer physical 269 
mixtures (PM) and pure drug was analysed in order to investigate if any re-crystallisation 270 
events registered over time (Figure 4). The XRPD pattern of ABZ shows intensity peaks at ș271 
angles of 6.91, 11.32, 13.83, 17.97, 19.51, 19.99, 20.75, 22.19, 23.85, 24.47, 24.72, 25.05, 272 
26.08, 26.23, 27.21, 28.73, 29.06, 30.00, 30.52 and 31.05° that correspond to ABZ crystalline 273 
form I (Pranzo et al., 2010). +RZHYHUWKHLQWHQVLW\RIWKHSHDNREVHUYHGDWșLVORZHU274 
compared to the one observed by Pranzo et al., (2010). This may be due to specimen 275 
preparation errors in the commercial ABZ pattern reported by Pranzo et al., such as crystals 276 
non-random preferred orientation (Jenkins and Snyder, 1996). 277 
The XRPD patterns of the physical drug-polymer mixtures (PM) and the extruded materials 278 
suggest the absence of a crystalline ordered structure of ABZ and the formation of an 279 
amorphous solid dispersion of the drug within the extruded polymer matrix. It can also be 280 
observed that by increasing ABZ content in the physical mixture (PM) samples, the height of 281 
the intensity peaks registered also increased (Fig. 4a). In contrast, the extruded materials do 282 
not show any intensity peaks relative to crystalline structures but a halo pattern characteristic 283 
of amorphous materials. By looking to the XRPD patterns obtained after 6 months storage of 284 
the extruded materials containing ABZ ± PVP K12 at 10/90 (% w/w) (Fig. 4b), we can 285 
conclude that the materials are stable and there are no re-crystallisation events registered over 286 
time. Therefore, these results suggest that stable amorphous solid dispersions of ABZ in PVP 287 
K12 for all formulations were achieved. 288 
3.5. Differential Scanning Calorimetry (DSC) 289 
DSC analysis of the extruded materials, physical mixtures (PM) and raw materials was 290 
carried out to determine the formation of amorphous solid dispersions and also evaluate the 291 
presence of glass transition (Tg) events (Fig. 5). Differences between the Tg values of the 292 
extruded ABZ formulations and physical mixtures (PM) drug-polymer (differences in scale to 293 
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be considered) indicated that a solid form transformation of the ABZ crystals occurred during 294 
HME and the extruded material thermograms do not show evidence of any endothermic event 295 
due to melting of crystalline material. Also, differences regarding Tg appearance is observed 296 
and is normally considered a middle value comprised by the Tg values of the raw materials 297 
involved (Maru et al., 2011; Baird and Taylor, 2012). Figure 6 shows the DSC thermograms 298 
of all extruded materials after 6 months storage. The presence of two Tg events for the 1/99% 299 
(w/w) at 25 °C, 5/95% (w/w) at 25 °C, 10/90% (w/w) at 50 °C curves suggests that the 300 
material could have evolved to a solid glassy suspension. However, there is no evidence of 301 
recrystallisation events, conclude that extruded materials are stable over time. Moreover, the 302 
1/99% (w/w) at 50 °C and 5/95% (w/w) at 50 °C appear to have one Tg event (solid 303 
dispersion), and the 10/90% (w/w) at 25 °C shows an amorphous curve without any Tg 304 
events due to the heating rate.  305 
3.6. Karl-Fischer studies for stability evaluation 306 
All the raw materials and extruded samples were analysed by Karl-Fischer titration to 307 
determine the water content, since the well-known hygroscopicity of some pharmaceutical 308 
grade polymers such as polyvinylpyrrolidone (PVP) can be a limitation due to its influence 309 
on the stability of amorphous solid dispersions (Bianco et al., 2013). Low water content 310 
values of dosage forms containing hygroscopic polymeric materials such as PVP constitute a 311 
crucial parameter to be evaluated as there is evidence indicating that intramolecular bonds of 312 
polymeric materials and therefore the polymer free volume and other properties like plasticity 313 
or elasticity can be affected by increases in water content (Szakonyi and Zelko, 2012). The 314 
water content within the samples is a quality attribute to ensure product stability and to 315 
preserve the product from degradation phenomena, often known as drug-polymer phase 316 
separation events (Rumondor and Taylor, 2009). Table 3 presents the water content (%) of 317 
the raw materials and the ABZ ± PVP K12 formulation at 10/90 (% w/w) observed at zero 318 
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and 6 months after storage. As depicted in Table 3, stored samples did not show water 319 
content increase higher than 0.2 % despite the high hygroscopicity properties of PVP. Non-320 
parametric ANOVA (Kruskal-Wallis) test was also performed indicating that temperature 321 
changes do not have a significant influence in samples water content (P=0.288 therefore 322 
P>0.05). Low water content values of 0.2 % are considered optimum for oral dosage forms in 323 
order to be stable and preserve their physicochemical properties. Solid dosage forms with 324 
water content values below 2 % are considered acceptable for a commercial pharmaceutical 325 
product although these values may differ depending on the type of product and specifications 326 
required. 327 
3.7. Dissolution profile studies 328 
Drug release of the extruded materials was characterised using a Sirius T3 measurement 329 
system under non-sink conditions and simulating gastrointestinal (GI) pH conditions. As can 330 
be observed in Figure 7, extruded materials (ABZ ± PVP K12 ratios of 1/99 and 10/90 (% 331 
w/w)) increased release compared to the pure drug with values of 70 % drug release and 332 
extrapolated dissolution rates of 45.09 µg min-1 and 148.80 µg min-1, respectively. Slightly 333 
lower values of 50 % drug release and extrapolated dissolution rate value of 171 µg min-1 334 
were achieved by the extruded material containing 5/95 (% w/w). Similar results related to 335 
solid dispersions of a BCS Class II drug such as ABZ into a PVP matrix that showed such an 336 
increase in drug dissolution rate and a similar dissolution profile were observed by Frizon et 337 
al., (2013). Dissolution profiles of the extruded materials of ABZ ± PVP K12 at 1/99 and 338 
5/95 % (w/w) did not achieve supersaturation (ABZ solubility below 22.8 µg/ml). However, 339 
supersaturation of the system was achieved by ABZ ± PVP K12 formulation at 10/90 % 340 
(w/w) with a solubility value of 30.33 µg/ml. It is of note in Figures 7 and 8 the increased and 341 
IDVW GUXJ UHOHDVH SURILOH RU DOVR FDOOHG ³VSULQJ´ RI WKH H[WUXGHG PDWHULDOV WKDW GRHV QRW342 
H[KLELWXQGHUWKHWHVWFRQGLWLRQVWKHFKDUDFWHULVWLF³SDUDFKXWH´HIIHFWREVHUYHGE\%URuwers 343 
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et al., (2009). In our studies, an optimum drug release profile close to 100 % was not 344 
achieved and possible influence of the polymeric material PVP K12 needs to be further 345 
studied. Tablets did completely dissolved in the buffer media which suggests there is an 346 
effect of PVP that prevents the complete dissolution of ABZ leading to different proportions 347 
(%) of drug released over time, although this needs to be further studied. Moreover, 348 
dissolution studies of the extruded materials stored for 6 months at 25 °C and 50 °C revealed 349 
that the formulations were stable over time (Fig. 8). Extruded materials comprising 1/99 % 350 
(w/w) show a similar dissolution profile after 6 months storage in comparison to 5/95 % and 351 
10/90% w/w which show variations of approximately 10% drug release. Similar 352 
improvements towards ABZ dissolution rate were achieved by Torrado et al., (1996) that 353 
manufactured successful amorphous solid dispersions of ABZ in PVP K12 by the classic 354 
solvent evaporation method and also carried out bioavailability studies in animals. We 355 
demonstrate the suitability of a lab scale HME process to obtain stable amorphous solid 356 
dispersions of ABZ with enhanced dissolution properties that could lead to novel 357 
formulations with enhanced oral bioavailability. 358 
4. Conclusions 359 
Amorphous solid dispersions of ABZ, an anthelmintic drug with poor water solubility 360 
properties, in PVP K12 matrix were produced by HME method. Evidence of solid form 361 
transformation of ABZ is proved by characterisation of the extruded materials using SEM, 362 
XRPD and DSC all of which indicate the formation of an amorphous drug polymer system. 363 
We also introduced a novel tool for the characterisation of HME materials, computed 364 
tomography (µ-CT), which provided an insight into internal material properties such as 365 
porosity and materials distribution indicating that despite the previous physicochemical 366 
results the strands are not homogeneous. The potential impact on pharmaceutical properties 367 
will have to be further investigated and maybe mitigated if the strands were pelletised or 368 
International Journal of Pharmaceutics 
 
16 
 
milled before further processing. Analysis of the samples after 6 months storage did not 369 
indicate any drug re-crystallisation events, which suggest that the samples were stable over 370 
time. Main factors involved are the use of a polymeric material with high Tg such as PVP 371 
K12 as well as the possibility of a complex formation between the drug and the polymer that 372 
will be further studied. High dissolution rate increase of ABZ in gastrointestinal simulated 373 
media was achieved with values of 70 % drug release for the extruded materials containing 374 
ABZ ± PVP K12 at 1/99 and 10/90 (% w/w). Six months storage under temperature 375 
controlled conditions did not affect the dissolution profiles and Karl-Fischer results showed 376 
that samples were not affected by water intake. To conclude, HME can be applied as a 377 
continuous manufacturing technique of novel oral dosage forms comprising ABZ without the 378 
need of further processing techniques in order to improve its dissolution behaviour and 379 
possible enhancement of oral bioavailability. 380 
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Figure captions 519 
Figure 1: Hot-stage microscopy (HSM, 10x magnification) images a to d: pure ABZ at 80 °C, 520 
145 °C, 180 °C and 210 °C, images e to g: physical mixture (PM) ABZ ± PVP K12 at 10/90 521 
(% w/w) at 80 °C, 145 °C and 180 °C. 522 
Figure 2: SEM images of pure drug (a), physical mixtures ABZ ± PVP K12 at 1/99, 5/95 and 523 
10/90 (% w/w) (b to d) and extruded materials of ABZ ± PVP K12 formulation at 1/99, 5/95 524 
and 10/90 (% w/w) (e to g). 525 
Figure 3: Micro-CT single scanned images of extruded materials of ABZ ± PVP K12 at 1/99, 526 
5/95 and 10/90 % (w/w) (a, b and c). 527 
Figure 4: Diffractograms of (a) ABZ ± PVP K12 formulations at time zero and (b) ABZ ± 528 
PVP K12 at a 10/90 (% w/w) ratio after 6 months storage. 529 
Figure 5: DSC thermograms of a: pure ABZ, b to d: physical mixtures (PM) of ABZ ± PVP 530 
K12 at 1/99 (% w/w), 5/95 (% w/w) and 10/90 (% w/w) and e to g: extruded materials of 531 
ABZ ± PVP K12 at 1/99 (% w/w), 5/95 (% w/w) and 10/90 (% w/w). 532 
Figure 6: DSC thermograms after 6 months storage where a: extruded material of ABZ ± 533 
PVP K12 at 1/99 % (w/w) at 25 °C, b: extruded material of ABZ ± PVP K12 at 1/99 % (w/w) 534 
at 50 °C, c: extruded material of ABZ ± PVP K12 at 5/95 % (w/w) at 25 °C, d: extruded 535 
material of ABZ ± PVP K12 at 5/95 % (w/w) at 50 °C, e: extruded material of ABZ ± PVP 536 
K12 at 10/90 % (w/w) at 25 °C and f: extruded material of ABZ ± PVP K12 at 10/90 % 537 
(w/w) at 50 °C. 538 
Figure 7: Dissolution profiles simulating gastrointestinal conditions of a: pure ABZ, b to d: 539 
physical mixtures (PM) of ABZ ± PVP K12 at 10/90 (% w/w), 5/95 (% w/w) and 1/99 (% 540 
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w/w) and e to g: extruded materials of ABZ ± PVP K12 at 5/95 (% w/w), 1/99 (% w/w) and 541 
10/90 (% w/w). Standard error bars are based on 2 tests per sample. 542 
Figure 8: Dissolution profiles simulating gastrointestinal conditions, upper left image 543 
(extruded material of ABZ ± PVP K12 at 1/99% (w/w)): a: pure ABZ, b: extrudate at time 544 
zero, c: extrudate after 6 months storage at 50 °C, d: extrudate after 6 months storage at 25 545 
°C; Upper right image (extruded material of ABZ ± PVP K12 at 5/95 % (w/w)): a: pure ABZ, 546 
b: extrudate after 6 months storage at 25 °C, c: extrudate after 6 months storage at 50 °C, d: 547 
extrudate at time zero; Lower image (extruded material of ABZ ± PVP K12 at 10/90 % 548 
(w/w)): a: pure ABZ, b: extrudate after 6 months storage at 25 °C, c: extrudate at time zero, 549 
d: extrudate after 6 months storage at 50 °C. 550 
  551 
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Table 1. HME processing parameters of ABZ ± PVP K12 formulations 
HME 
formulation 
 
Barrel 
Zones 
Barrel temperatures 
(°C, zones 1, 2, 3 and 4-8) 
Screw 
speed 
(rpm) 
Torque 
(Nm) 
Throughput 
(Kg/h) 
F1 1 - 8 70, 120, 140, 145 100 1.2 - 3 0.1 - 0.15 
F2 1 - 8 70, 120, 140, 145 100 1.2 - 3 0.15 
F3 1 - 8 70, 120, 140, 145 100 1.2 - 2.7 0.1 - 0.15 
 
Description: 
Table 1 shows the HME processing parameters applied for the development of three 
formulations comprising Albendazole (ABZ) and PVP K12 such as barrel temperatures and 
screw speed. Further information such as the torque values registered and the total throughput 
are also given. 
  552 
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Table 2. Morphometric parameters of extruded materials obtained by µ-CT 3D analysis 553 
HME 
formulation 
 
Object volume 
(mm3) 
Volume closed 
pores (mm3) Closed porosity (%) 
F1 25.17 0.01 0.04 
F2 26.17 0.65 2.43 
F3 12.70 0.20 1.57 
 554 
Description: 
Table 2 above shows the µ-CT 3D analysis of the extruded materials such as the object 555 
volume, defined as the total volume analysed based on the external dimensions of the strand 556 
(diameter approximately 2.0 mm) and the closed pores, defined as the space within the object 557 
volume, which is completely surrounded by solid material. 558 
  559 
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Table 3. Karl-Fischer results after storage 
Materials Storage conditions Average water content (% w/w) 
Extruded material 
ABZ ± PVP K12 10/90 
(% w/w) ratio 
Time zero, room temperature 0.1591 ± 0.0084 
6 months at 25 °C, 20% RH 0.1445 ± 0.0387 
6 months at 50 °C, 3% RH 0.1796 ± 0.0037 
 
Description: 
Table 3 above shows the average water content values (% w/w) obtained by Karl-Fischer 
coulometric titration using methanol as dissolution media. Mean standard deviation (SD) 
values of 3 replicates calculated for each sample are depicted using ± symbol (Kruskal-Wallis 
test, P=0.288 therefore P>0.05). 
 
 
